Увійти

Готові списки джерел за темами / Brody syndrome / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Brody syndrome.

Статті в журналах з теми "Brody syndrome"

Автор: Grafiati

Опубліковано: 11 березня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Brody syndrome".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Voermans, N. C., A. E. Laan, A. Oosterhof, T. H. van Kuppevelt, G. Drost, M. Lammens, E. J. Kamsteeg, et al. "Brody syndrome: A clinically heterogeneous entity distinct from Brody disease." Neuromuscular Disorders 22, no. 11 (November 2012): 944–54. http://dx.doi.org/10.1016/j.nmd.2012.03.012.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Glowinski, J., O. Dubourg, I. Amoura, and F. Bouguetof. "Syndrome de Brody — 1 cas." La Revue de Médecine Interne 23 (December 2002): 639s—640s. http://dx.doi.org/10.1016/s0248-8663(02)80572-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Guglielmi, V., N. C. Voermans, A. Oosterhof, D. Nowis, B. G. van Engelen, G. Tomelleri, and G. Vattemi. "Evidence of ER stress and UPR activation in patients with Brody disease and Brody syndrome." Neuropathology and Applied Neurobiology 44, no. 5 (July 18, 2018): 533–36. http://dx.doi.org/10.1111/nan.12431.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Guglielmi, Valeria, Gaetano Vattemi, Francesca Gualandi, Nicol C. Voermans, Matteo Marini, Chiara Scotton, Elena Pegoraro, et al. "SERCA1 protein expression in muscle of patients with Brody disease and Brody syndrome and in cultured human muscle fibers." Molecular Genetics and Metabolism 110, no. 1-2 (September 2013): 162–69. http://dx.doi.org/10.1016/j.ymgme.2013.07.015.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Ben Achour, N., N. Kessentini, I. Kraoua, and I. Ben Youssef-Turki. "Enraidissement musculaire et crampes chez un enfant : penser au syndrome de Brody." Archives de Pédiatrie 22, no. 8 (August 2015): 897–98. http://dx.doi.org/10.1016/j.arcped.2015.05.002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Voermans, N. C., A. E. Laan, A. Oosterhof, A. van Kuppevelt, G. Drost, M. Lammens, E. J. Kamsteeg, et al. "G.P.103 Brody syndrome: a clinically heterogeneous entity distinct from Brody disease: A review of literature and a cross-sectional clinical study in 17 patients." Neuromuscular Disorders 22, no. 9-10 (October 2012): 899. http://dx.doi.org/10.1016/j.nmd.2012.06.316.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Pérez, Rufino de Jesús Solís, Pamela Irene Baas Argaez, Alfonso Franco Navarro, and David Leal Mora. "Síndrome de Meigs o pseudomeigs en nonagenaria." South Florida Journal of Health 4, no. 1 (January 9, 2023): 1–6. http://dx.doi.org/10.46981/sfjhv4n1-001.

Повний текст джерела

Анотація:

INTRODUCCIÓN La aparición del síndrome de Meigs o pseudomeigs caracterizado por presencia de tumor ovárico, ascitis, derrame pleural es menos frecuente en este grupo de edad por lo que es infradiagnosticado retrasando el tratamiento oportuno. Debido a eso es detectado hasta en estadios avanzados ocasionando disfuncionalidad en poco tiempo. CASO CLÍNICO Mujer de 91 años conocida con hipertensión arterial sistémica, Diabetes Mellitus, uso de bastón monopodálico, con valoración geriátrica inicial: Katz A-B-G, Lawton y Brody 7-3-1, Barthel 85-75-35, pre frágil, sin queja de memoria. Acudió por hiporexia de 1 mes de evolución, evacuaciones diarreicas asociados a episodios de incontinencia fecal, disnea que progreso a pequeños esfuerzos, ascitis y edema de miembros inferiores. CONCLUSIÓN Es importante considerar estos síndromes como diagnóstico diferencial en pacientes que presenten súbitamente derrame pleural, ascitis o ambos con el fin de no retrasar el tratamiento oportuno y preservar la funcionalidad en el mayor grado posible. Background The appearance of Meigs syndrome or pseudomeigs characterized by the presence of an ovarian tumor, ascites, pleural effusion is less frequent in this age group, which is why it is underdiagnosed, delaying timely treatment. Because of this, it is detected even in advanced stages, causing dysfunction in a short time. Clinical Case A 91-year-old woman with systemic arterial hypertension, Diabetes Mellitus, use of monopodal with initial geriatric assessment: Katz A-B-G, Lawton and Brody 7-3-1, Barthel 85-75-35, pre-frail, without complaint of memory. He came due to hyporexia of 1 month evolution, diarrhea associated with episodes of fecal incontinence, dyspnea that progressed with small efforts, ascites and edema of the lower limbs. Conclusión It is important to consider these syndromes as a differential diagnosis in patients who suddenly present with pleural effusion, ascites, or both in order not to delay timely treatment and to preserve functionality to the greatest possible degree.

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Fhon, Jack Roberto Silva, Rosalina Aparecida Partezani Rodrigues, Jair Lício Ferreira Santos, Marina Aleixo Diniz, Emanuella Barros dos Santos, Vanessa Costa Almeida, and Suelen Borelli Lima Giacomini. "Factors associated with frailty in older adults." Revista de Saúde Pública 52 (August 3, 2018): 74. http://dx.doi.org/10.11606/s1518-8787.2018052000497.

Повний текст джерела

Анотація:

OBJECTIVE: To determine the demographic and health factors related to the frailty syndrome in older adults. METHODS: This is a longitudinal quantitative study carried out with 262 older adults aged 65 years and older, of both sexes, living at home. Data collection was carried out in Period 1 between October 2007 and February 2008, and in Period 2 between July and December 2013. For data collection, we used the sociodemographic profile instrument, the Edmonton Frail Scale, the Mini-Mental State Examination, the number of falls in the last 12 months, the number of self-reported diseases and used drugs, the Functional Independence Measure, and the Lawton and Brody Scale. We used descriptive statistics for data analysis, in the comparison of the means between periods, the nonparametric Wilcoxon test, and the method of Generalized Estimating Equations, which is considered an extension of the Generalized Linear Models with p ≤ 0.05. RESULTS: Of the 515 participants, 262 completed the follow-up, with a predominance of females, older individuals, and those who had no partner; there was an increase in frail older adults. In the Generalized Estimating Equations analysis, frailty score was related to sociodemographic (increase in age, no partner, and low education level) and health variables (more diseases, drugs, falls, and decrease in functional capacity). There was an association between the variables of age (older), marital status (no partner), and loss of functional capacity. CONCLUSIONS: Frailty syndrome was associated with increasing age, having no partner, and decreased functional capacity over time, and investments are required to prevent this syndrome and promote quality in aging.

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Buckstein, Rena, Richard A. Wells, Nancy Zhu, Thomas J. Nevill, Heather A. Leitch, Karen W. L. Yee, Brian Leber, et al. "Patient Related Factors Have an Indepedent Impact on Overall Survival in Myelodysplastic Syndrome Patients: A Report of the MDS-Can Registry." Blood 124, no. 21 (December 6, 2014): 165. http://dx.doi.org/10.1182/blood.v124.21.165.165.

Повний текст джерела

Анотація:

Abstract Introduction: MDS is a disease of the elderly; yet, the impact of clinical frailty (an age-related vulnerability state created by a multidimensional loss of reserves) and patient-reported outcomes on overall survival (OS) are unknown. Rockwood et al. have developed a simple 9-point clinical frailty scale (CFS) that correlated highly with the risk of death, institutionalization, worsening health and hospital use (Rockwood K., CMAJ 2005). In a prospective, national MDS registry, participants have undergone annual evaluations with the following: (a) 3 geriatric physical performance tests, (b) Charlson (CCI) and Della Porta comorbidity index (DP-CCI) scores, (c) graded frailty using the Rockwood CFS, (d) disability assessments with the Lawton Brody SIADL, and (e) QOL using the EORTC QLQ C-30 and the EQ-5D. The results of these frailty assessments and the effects of these patient-related factors and reported outcomes on OS, in addition to the IPSS/revised IPSS, will be presented. Methods: Overall survival was measured from time to enrollment. Results from physical performance tests were divided into quintiles with higher scores indicating better performance. We used univariate and multivariable Cox proportional hazard model to determine significant predictive factors of overall survival (OS). The variables considered included age, IPSS, R-IPSS, ferritin, LDH, transfusion dependence, hemoglobin (hgb), ECOG, frailty, CCI and DP-CCI, grip strength, 4 M walk test, stand-sit test, modified short physical performance battery (SPPB), Lawton Brody SIADL, time from diagnosis and selected QOL domains including the EQ-5D summary score, EORTC physical functioning, dyspnea and fatigue scores. Results: 453 MDS patients (pts) have been consented and enrolled locally since January 2008 (n=231) and nationally since January 2012 (n=222). Median time from diagnosis was 5.8 mos (IQR 1.4-21). Median age was 73 y (range, 26-95 y), 65% were male and the R-IPSS scores were very low (14%), low (46%), intermediate (24%), high (10%) and very high (6%). Thirty-three % of pts were transfusion dependent at enrollment. Median CCI and DP-CCI scores were 1 (0-12) and 0 (0-6) respectively with 18% and 24% falling into the highest category scores. Median frailty scale score (n=346) was 3 (1-9) with 25% having scores indicating moderate (4-5) or severe (6-9) frailty. The CCI and DP-CCI strongly correlated (r=0.6; p< .0001) with each other, while frailty significantly but modestly correlated with them (r=0.3-0.35, p<.0001). With a median follow up (from enrollment) of 15 mos (95% CI: 13-16), 159 (35%) pts have died and 28 pts lost to follow up. Actuarial survival was 41.0 mos (range, 33.6 - 48.5 mos). When considering patient related factors - age, frailty, comorbidity (both indices), sex, ECOG, the 10 x stand sit test, the SPPB, Lawton Brody SIADL, and all QOL domains considered above were significantly predictive of OS. The multivariable model with the highest R2 included R-IPSS (p=.0004), frailty (1-3 vs 4-9, p= .004), CCI (0-1 vs >2, p=.03) and EORTC fatigue (p=.01) as summarized in Table 1 below. A frailty score > 3 predicted for worse survival (figure 1: 2 year OS 68.5% vs. 83.8%) and further refined survival within the R-IPSS categories (Figure 2). Frailty was also the single most predictive factor for OS from the start of azacitidine therapy (not shown). Conclusions: Patient-related factors such as frailty and comorbidity (that evaluate physiologic reserve and global fitness) should be considered in addition to traditional MDS prognostic indices. Abstract 165. Table. Independent Covariate Predictive factors at baseline Coefficient SE p -value HR 95% CI of HR R2 (%) Time from diagnosis (months) * 0.0335 0.1076 0.7557 1.034 0.837 1.277 17.29% R-IPSS (5 categories) <.0001 Very high vs. very low 2.5701 0.7289 0.0004 13.066 3.131 54.524 High vs. very low 2.1156 0.6437 0.0010 8.294 2.349 29.285 Intermediate vs. very low 1.0466 0.6430 0.1036 2.848 0.808 10.043 Low vs. very low 0.6346 0.6181 0.3045 1.886 0.562 6.334 Frailty (1-3 vs. 4-9) -0.8323 0.2905 0.0042 0.435 0.246 0.769 Comorbidity Charlson (0-1 vs. ³2) -0.5915 0.2749 0.0314 0.553 0.323 0.949 EORTC fatigue * 0.3671 0.1546 0.0176 1.443 1.066 1.954 natural log-transformation was applied for normalizing distribution Figure 1 Overall survival by Frailty (n=346) Figure 1. Overall survival by Frailty (n=346) Figure 2 Overall Survival by Frailty and R-IPSS Figure 2. Overall Survival by Frailty and R-IPSS Disclosures Buckstein: Celgene Canada: Research Funding. Wells:Celgene: Honoraria, Other, Research Funding; Novartis: Honoraria, Research Funding; Alexion: Honoraria, Research Funding. Leitch:Alexion: Honoraria, Research Funding; Novartis: Honoraria, Research Funding, Speakers Bureau; Celgene: Educational Grant Other, Honoraria, Research Funding. Shamy:Celgene: Honoraria, Other.

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Piñón, Miguel, Emilio Paredes, Beatriz Acuña, Sergio Raposeiras, Elena Casquero, Ana Ferrero, Ivett Torres, et al. "Frailty, disability and comorbidity: different domains lead to different effects after surgical aortic valve replacement in elderly patients." Interactive CardioVascular and Thoracic Surgery 29, no. 3 (April 10, 2019): 371–77. http://dx.doi.org/10.1093/icvts/ivz093.

Повний текст джерела

Анотація:

Abstract OBJECTIVES Frailty syndrome predicts adverse outcomes after surgical aortic valve replacement. However, disability or comorbidity is frequently associated with preoperative frailty evaluation. The effects of these domains on early and late outcomes were analysed. METHODS A prospective study including patients aged ≥75 years with symptomatic severe aortic stenosis who received aortic valve replacement with or without coronary artery bypass grafting was conducted. We used the Cardiovascular Health Study Frailty Phenotype to assess frailty, the Lawton–Brody index to define disability and the Charlson comorbidity index (CCI) to evaluate comorbidity. RESULTS Frailty was identified in 57 (31%), dependence in 18 (9.9%) and advanced comorbidity (CCI ≥ 4) in 67 (36.6%) of the 183 enrolled patients. Operative mortality (1.6%), transfusion rate and duration of stay increased in patients with CCI ≥4 (P < 0.005). There was a non-significant trend for these adverse outcomes among the frail patients. Follow-up was achieved in all patients (median/interquartile range 869/699–1099 days). Kaplan–Meier univariable analysis showed a reduced survival rate for frail and dependent patients and for those with multiple comorbidities (P < 0.05). According to multivariable analysis, frailty and comorbidity were independent risk factors for 1-year mortality, while disability and comorbidity, but not frailty, were risk factors for 3-year mortality (P < 0.05). CONCLUSIONS Surgical aortic valve replacement in patients aged ≥75 years is a safe procedure with low mortality rates. Operative outcomes are mainly affected by comorbidities. The main influence of survival occurs throughout the first year, and an improved functional status prevents any progression towards disabilities, which could potentially benefit long-term outcomes. Clinical trial registration number NCT02745314

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Janssens, Wim, Rik Willems, Dirk Pevernagie, and Bertien Buyse. "REM sleep-related brady-arrhythmia syndrome." Sleep and Breathing 11, no. 3 (March 21, 2007): 195–99. http://dx.doi.org/10.1007/s11325-007-0105-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

BAROLD, S. SERGE. "Optimal Pacing in the Brady-Tachy Syndrome." Cardiology in Review 5, no. 2 (March 1997): 63–71. http://dx.doi.org/10.1097/00045415-199703000-00004.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Efthymiou, Christopher Andrew, and James Andrew Charles Thorpe. "Thymic cyst presenting as tachy-brady syndrome." European Journal of Cardio-Thoracic Surgery 35, no. 6 (June 2009): 1108–10. http://dx.doi.org/10.1016/j.ejcts.2009.02.024.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Ilhan, Erkan, F. Russell Quinn, Derek V. Exner, L. Brent Mitchell, and George D. Veenhuyzen. "A unique form of a brady-tachy syndrome." Pacing and Clinical Electrophysiology 40, no. 7 (June 30, 2017): 894–96. http://dx.doi.org/10.1111/pace.13120.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Kabul, H. K., U. Küçük, C. Barçın, H. O. Küçük, M. Yokuşoglu, and S. Kose. "PP-305 REM SLEEP RELATED BRADY ARRHYTHMIA SYNDROME." International Journal of Cardiology 163, no. 3 (March 2013): S204—S205. http://dx.doi.org/10.1016/s0167-5273(13)70509-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Т.В., Кожанова,, Жилина, С.С., Мещерякова, Т.И., Лукьянова, Е.Г., Сушко, Л.М., Осипова, К.В., Айвазян, С.О., Притыко, А.Г., and Заваденко, Н.Н. "Ververi-Brady syndrome associated with QRICH1 variants (clinical cases)." Nauchno-prakticheskii zhurnal «Medicinskaia genetika, no. 2 (February 28, 2022): 23–31. http://dx.doi.org/10.25557/2073-7998.2022.02.23-31.

Повний текст джерела

Анотація:

В последние десятилетия достижения в области применения полноэкзомных и полногеномных технологий секвенирования позволили идентифицировать большое количество генов, связанных с умственной отсталостью, включая редкие формы, в частности, ассоциированные с мутациями в гене QRICH1. Синдром Вервери-Брэди (СВБ; MIM# 617982) - редкий синдром с аутосомно-доминантным типом наследования, характеризуется нарушением интеллекта, задержкой речи и легкими дисморфическими чертами лица. Впервые в России представлено клиническое и молекулярное описание двух пациентов с эпилепсией, задержкой развития и речи, мягкими дисморфическими чертами лица. При полноэкзомном секвенировании выявлены варианты нуклеотидной последовательность в гене QRICH1 -миссенс-мутация (c.1711G>A; p. Asp571Asn) и мутация сдвига рамки считывания (c.1963_1964insT; p.Lys655IlefsTer). На сегодняшний день в мире зарегистрировано 38 пациентов с мутациями в гене QRICH1. Recent advances in sequencing technologies have enabled identification of multiple genes associated with intellectual disability disorders, including QRICH1 gene. Ververi-Brady syndrome (VBS; MIM: #617982) is a rare developmental disorder, characterized by mild developmental delay, mildly impaired intellectual development and speech delay and mild dysmorphic facial features. For the first time in Russia, clinical and molecular description of two patients with epilepsy, developmental and speech delay, and mild dysmorphic facial features is presented. The variants nucleotide sequence in QRICH1 gene - missense mutation (c.1711G>A; p. Asp571Asn) and frameshift mutations (c.1963_1964insT; p.Lys655IlefsTer) were detected by whole exome sequencing. To date, thirty-eight individuals have been reported with QRICH1 mutations in the world.

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Mohd Adib, M. A. H., and N. H. M. Hasni. "Enhanced Brady-Tachy Heart Automotive (BT-Heartomotive) Device for Heart Rate Monitoring during Driving." International Journal of Automotive and Mechanical Engineering 17, no. 1 (April 8, 2020): 7599–606. http://dx.doi.org/10.15282/ijame.17.1.2020.09.0564.

Повний текст джерела

Анотація:

Driving with brady-tachy syndrome is one of the main causes of car accidents. In order to prevent drivers from brady-tachy driving, there is a strong demand for driver monitoring systems. Other than problems in driving attitudes and skills, road accidents are also caused by uncontrollable factors such as medical conditions and drowsiness. These factors can be avoided by having early detection. Therefore, the brady-tachy heart automotive so-called BT-Heartomotive device is developed. This BT-Heartomotive device can detect early signs of drowsiness and health problems by measuring the heart rate of the drivers during driving. The device also could use the data to send an alert to the passengers that they’re in precaution. The device shows a good accuracy in the detection of the heart rate level. The device comprised three main components; wristband, monitor and integrated mobile applications. Heart rate measurement can reveal a lot about the physical conditions of an individual. The BT-Heartomotive device is simple, easy to use and automated.

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Abaoğlu, Hatice, Emre Mutlu, Sertaç Ak, Esra Akı, and A. Elif Anıl Yağcıoğlu. "M221. THE EFFECT OF LIFE SKILLS TRAINING ON FUNCTIONING IN SCHIZOPHRENIA: A RANDOMIZED CONTROLLED TRIAL." Schizophrenia Bulletin 46, Supplement_1 (April 2020): S220. http://dx.doi.org/10.1093/schbul/sbaa030.533.

Повний текст джерела

Анотація:

Abstract Background The combined use of pharmacological and non-pharmacological psychosocial interventions is seen as the most effective treatment approaches to improve the long term outcomes in schizophrenia. The psychosocial interventions aim to improve social skills, self-efficacy, being independent in activities of daily living and interpersonal communication in people diagnosed with schizophrenia. They include various approaches, such as cognitive behavioral therapy, cognitive remediation, individual, group or family therapies and life skills trainings. Life skills training approaches aim to assist individuals gain skills necessary for fulfilling their roles in the environment they live in, and consist of parts including assessment, teaching, behavioral practice, feedback, and homework, covering areas such as self-care, money management, communication and social skills, home management and community life. In this study, we planned to investigate the effects of individualized life skills training on the functionality of individuals diagnosed with schizophrenia. Methods A total of 32 individuals diagnosed with schizophrenia were assigned randomly to the life skills training (n=15) and the control groups (n=17). The participants were assessed with the Positive and Negative Syndrome Scale (PANSS) for symptom severity, the Clinical Global Impression Scale for illness severity, improvement and response to treatment, the Katz Index of Independence in Activities of Daily Living and the Lawton – Brody Instrumental Activities of Daily Living Scale for adequacy of performance of basic activities and tasks of daily living, the Functioning Assessment Short Test and Social Functioning Scale for level of functionality before and after the scheduled interventions in both groups. The control group received a single-session awareness training to increase independence in daily living activities, and the life skills training group received individualized life skills training in 2 sessions per week for 8 weeks (i.e. 16 sessions). Results The life skills training and control groups did not differ significantly on the bases of age, gender, working status, marital status, education (years), age at onset and duration of illness. The groups were similar in terms of pharmacological treatment choices. At the end of the research program, improvements were observed in the negative symptoms, general psychopathology, severity of illness and independence in basic and instrumental activities of daily living and functioning in the life skills training group as compared to the control group. Discussion Our study showed that the training planned to improve life skills in individuals with chronic schizophrenia during the transition period from the hospital to the community environment, decreased negative symptoms and had a positive effect on general psychopathology and illness severity. Individual based life skills training, which focused less on social learning principles and aimed to increase independence in daily life, demonstrated positive effects on patient functionality. On the basis of the obtained results, it can be suggested that individualized life skills training may be an effective therapeutic method for the rehabilitation of individuals diagnosed with schizophrenia. The effect of individualized life skills training should be investigated and supported by long-term follow-up studies.

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Namboodiri, Narayanan, Shomu Bohora, Valaparambil K. Ajitkumar, and Jaganmohan A. Tharakan. "A case of ‘tachy-brady syndrome’: What is the mechanism?" Indian Pacing and Electrophysiology Journal 15, no. 5 (September 2015): 261–64. http://dx.doi.org/10.1016/j.ipej.2016.03.001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Blunt, Danielle N., Richard A. Wells, Martha Lenis, Lisa Chodirker, Michelle Geddes, Nancy Zhu, Jill Fulcher, et al. "Health Related Quality of Life Remains Stable over Time in Myelodysplastic Syndrome: An MDS-CAN Prospective Study." Blood 132, Supplement 1 (November 29, 2018): 4850. http://dx.doi.org/10.1182/blood-2018-99-114327.

Повний текст джерела

Анотація:

Abstract Background: Health-Related Quality of life (HRQoL) is diminished in patients with myelodysplastic syndrome (MDS). We have previously shown that HRQoL remains stable over time and low hemoglobin, transfusion dependence (TD) and age > 65 years impact QoL1. Here, we present an updated larger data set with longer follow up and consider the impact of baseline characteristics and treatments received on patient-related outcomes. Methods: MDS-CAN is a prospective database active in 15 centers across Canada, enrolling patients since April 2012. In addition to disease and patient-related characteristics, we measure HRQoL at baseline and every 6 months using the EORTC-QLQ-C30, EQ-5D, and a global fatigue scale (GFS). We examined the impact of disease related factors (IPSS, IPSS-R, karyotype, TD), patient factors (ECOG, age, gender, co-morbidity (Charlson index), frailty (Rockwood scale), disability (Lawton-Brody Independent Activities of Daily Living), and treatments received at any time (azacitidine (AZA), lenalidomide, erythropoietin-stimulating agents (ESA), iron chelation) on QoL scores. AZA-treated patients were divided into responders (where documented) or deriving benefit (if > 6 cycles) vs. non-responders. Wilcoxon rank-sum or Kruskal-Wallis nonparametric tests were used to compare scores among subgroups. Changes in QoL were assessed with a linear mixed model to account for time- dependent covariates such as TD, risk scores and treatment. Results: 594 patients were enrolled a median of 2.2 months post diagnosis (IQR: 0.8, 4.8) with a median age of 73 years , 63% male gender and performance status (ECOG) of 0-1 in 90%. IPSS scores were low/int-1 in 73% and IPSS-R scores were very low (9%), low (30%), intermediate (27%), high (20%) and very high (14% of patients). 31% were transfusion dependent at enrolment. Treatments received at any time included AZA (38%), lenalidomide (9.8%), ESA (35%) and iron chelation (12%). At a median follow up of 17 months, 329 patients (55%) died with cause of death reported as AML in 22%. Baseline assessment: Mean EQ-5D global score for the cohort was 0.75 ± 0.25 and did not significantly change over time (Figure 1). Patients with high IPSS, high/very high IPSS-R, TD, lower hemoglobin, higher ECOG, increased comorbidity, frailty and disability were more likely to have lower EQ-5D/QLQ C30 scores (inferior QoL) and higher fatigue (GFS). Age was not significantly related to QoL. Interestingly, female gender was associated with inferior QoL by EQ-5D and GFS (Figure 2). Patients scoring in the lowest quartiles for physical performance tests (grip, 4 metre walk and 10x chair sit-stand tests) also had inferior QoL scores. QoL over time: By linear mixed modelling, we did not find significant differences in QoL over time in patients treated with or without AZA, lenalidomide, or ESAs measured by the EQ-5D instrument. Iron chelation was associated with lower scores (p=0.003) although this may simply be a surrogate for transfusion dependence which is associated with inferior QoL. AZA responding/deriving benefit patients had higher QoL scores from baseline and decreased fatigue compared with those not responding or not deriving benefit (Figure 3) measured by the QLQ-C30 and GFS instruments. Patients with the highest IPSS/IPSS-R risk groups had significantly inferior QoL over time. In conclusion, this study demonstrates that HRQoL remains fairly stable over time in MDS and implementation of treatment is not at the detriment of patient related outcomes. Patients treated with AZA who respond or remain on drug for > 6 months maintain higher QoL scores over time. Disease (IPSS, IPSS-R, hemoglobin, transfusion dependence) and patient-related factors (ECOG, gender, comorbidities, disability, frailty) are associated with reduced HRQoL. The prospective assessment of QoL using a validated MDS-specific QoL instrument (QUALMS) and disease course is underway. 1 Buckstein, R., Alibhai, S.M., Lam, A., et al. The health-related quality of life of MDS patients is impaired and most predicted by transfusion dependence, hemoglobin and age. Leukemia Research. May 2011 Vol 35, Supplement 1, Pages S55-56. Disclosures Wells: Alexion Pharmaceuticals, Inc.: Honoraria, Other: Travel Support , Research Funding; Novartis: Honoraria; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Geddes:Alexion: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding. Zhu:Janssen: Consultancy; Novartis: Consultancy; Celgene: Consultancy, Research Funding. Sabloff:Celgene: Membership on an entity's Board of Directors or advisory committees. Keating:Bayer: Honoraria, Membership on an entity's Board of Directors or advisory committees. Leber:Novartis Canada: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis Canada: Honoraria, Membership on an entity's Board of Directors or advisory committees. Leitch:Novartis: Honoraria, Research Funding, Speakers Bureau; Celgene: Honoraria, Research Funding; Alexion: Honoraria, Research Funding; AbbVie: Research Funding. Yee:Celgene, Novartis, Otsuka: Membership on an entity's Board of Directors or advisory committees; Agensys, Astex, GSK, Onconova, Genentech/Roche: Research Funding. St-Hilaire:Novartis: Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Shamy:Amgen: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees. Elemary:Roche: Membership on an entity's Board of Directors or advisory committees; Lundbeck: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding. Delage:Celgene: Membership on an entity's Board of Directors or advisory committees; AbbVie: Research Funding; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Research Funding; BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding. Rockwood:Pfizer: Research Funding; Lundbeck: Membership on an entity's Board of Directors or advisory committees; CHIR: Research Funding; Nova Scotia Health research foundation: Research Funding; Sanofi: Research Funding; Capital Health research support: Research Funding; Canadian consortium on neurodegeneration in aging and nutricia: Membership on an entity's Board of Directors or advisory committees; Alzheimer Society of Canada: Research Funding; Foundation Family Fund: Research Funding. Banerji:Teva: Other: Unrestricted grant received in the past; Gilead: Other: Unrestricted grant received in the past; Abbvie: Other: Unrestricted grant received in the past; Roche: Other: Unrestricted grant received in the past; Janssen: Other: Unrestricted grant received in the past. Buckstein:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Han, Qiaoyu, Lu Wang, Luyang Jiang, Yi Feng, Yu Chen, Shenglong Chen, and Qing Gao. "Tachy-brady syndrome induced by a transversus thoracis muscle plane block." Journal of Clinical Anesthesia 73 (October 2021): 110327. http://dx.doi.org/10.1016/j.jclinane.2021.110327.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Dunnigan, Ann, and Simón Milstein. "Brady-tachy syndrome in the postoperative patient: Evaluation and case management." Progress in Pediatric Cardiology 3, no. 4 (November 1994): 236–47. http://dx.doi.org/10.1016/s1058-9813(05)80012-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

RACZAK, GRZEGORZ, GRAZYNA SWIATECKA, ANDRZEJ LUBINSKI, and JACEK KUBICA. "Transesophageal Atrial Pacing Complications in Patients Suspected of Tachy-Brady Syndrome." Pacing and Clinical Electrophysiology 13, no. 12 (December 1990): 2048–53. http://dx.doi.org/10.1111/j.1540-8159.1990.tb06940.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Ruciński, Piotr, Andrzej Kutarski, and Leszek Wdowiak. "Cost of care distribution in brady-tachy syndrome after pacemaker implantation." Heart Rhythm 2, no. 5 (May 2005): S24. http://dx.doi.org/10.1016/j.hrthm.2005.02.085.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Rucinski, P., A. Kutarski, and L. Wdowiak. "774 Cost of care distribution in brady-tachy syndrome after pacemaker implantation." EP Europace 7, Supplement_1 (2005): 176. http://dx.doi.org/10.1016/eupace/7.supplement_1.176.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Tselios, K., D. D. Gladman, P. Harvey, J. Su, and M. B. Urowitz. "Severe brady-arrhythmias in systemic lupus erythematosus: prevalence, etiology and associated factors." Lupus 27, no. 9 (April 17, 2018): 1415–23. http://dx.doi.org/10.1177/0961203318770526.

Повний текст джерела

Анотація:

Background Severe brady-arrhythmias, requiring a permanent pacemaker (PPM), have been sparsely reported in systemic lupus erythematosus (SLE). The aim of this study was to describe the characteristics of such arrhythmias in a defined lupus cohort. Patients and methods The database of the Toronto Lupus Clinic ( n = 1366) was searched for patients who received a PPM. Demographic, clinical, immunological and therapeutic variables along with electrocardiographic (ECG) and echocardiographic findings (based on the last available test prior to PPM) were analyzed. Patients with a PPM (cases) were compared with age-, sex- and disease duration-matched patients without a PPM (controls). Analysis was performed with SAS 9.0; p < 0.05 was considered significant. Results Eighteen patients were identified, 13 (0.95%) with complete atrioventricular block and 5 (0.37%) with sick sinus syndrome. Disease duration at PPM implantation was 22 ± 12 years. Compared to controls, cases had more frequently coronary artery disease, hypertension, dyslipidemia and longer antimalarial (AM) treatment duration. The prevalence of first-degree atrioventricular block, right bundle branch block, left anterior fascicular block and septal hypertrophy was also higher. AM treatment was significantly associated with brady-arrhythmias (OR = 1.128, 95% CI = 1.003–1.267, p = 0.044). Nine patients had prior heart disease and one received a PPM two years after renal transplantation. Eight patients did not have any potential risk factors; prolonged AM therapy (mean 22 years) might have been the cause. Conclusions Apart from known causes, prolonged AM treatment may be associated with severe brady-arrhythmias in SLE. Certain ECG and echocardiographic characteristics may represent indicators of an ongoing damage in the conduction system.

Стилі APA, Harvard, Vancouver, ISO та ін.

27

McCORMICK, DANIEL J., JOHN W. SHUCK, and RICHARD A. ANSINELLI. "Intermittent Pacemaker Syndrome: Revision of VVI Pacemaker to a New Cardiac Pacing Mode for Tachy-Brady Syndrome." Pacing and Clinical Electrophysiology 10, no. 2 (March 1987): 372–77. http://dx.doi.org/10.1111/j.1540-8159.1987.tb05975.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Ruttkay, Tamas, Julia Götte, Ulrike Walle, and Nicolas Doll. "Minimally Invasive Cardiac Surgery Using a 3D High-Definition Endoscopic System." Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 10, no. 6 (November 2015): 431–34. http://dx.doi.org/10.1097/imi.0000000000000216.

Повний текст джерела

Анотація:

We describe a minimally invasive heart surgery application of the EinsteinVision 2.0 3D high-definition endoscopic system (Aesculap AG, Tuttlingen, Germany) in an 81-year-old man with severe tricuspid valve insufficiency. Fourteen years ago, he underwent a Ross procedure followed by a DDD pacemaker implantation 4 years later for tachy-brady-syndrome. His biventricular function was normal. We recommended minimally invasive tricuspid valve repair. The application of the aformentioned endoscopic system was simple, and the impressive 3D depth view offered an easy and precise manipulation through a minimal thoracotomy incision, avoiding the need for a rib spreading retractor.

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Archakov, Evgeniy A., R. E. Batalov, S. V. Popov, A. V. Smorgon, E. F. Muslimova, and S. A. Afanasiev. "Influence of risk factors and polymorphism of casq2 gene on development of atrial fibrillation in combination with sick sinus node syndrome." Clinical Medicine (Russian Journal) 96, no. 9 (December 30, 2018): 804–8. http://dx.doi.org/10.18821/0023-2149-2018-96-9-804-808.

Повний текст джерела

Анотація:

The aim of the study was to evaluate the influence of risk factors on the development of a combination of atrial fibrillation and sick sinus node syndrome and to determine the relationship of these cardiac arrhythmias to the polymorphism of the CASQ2 gene. The study included 95 patients, mean age 61.1 ± 14.3 years; Of them men - 48 (50.5%), with AF - 38 (40.0%), SSS - 17 (17.9%) and their combination - 40 (42.1%). Patients are divided into 3 groups, depending on the type of heart rhythm disturbance. The analysis of polymorphism rs6684209 of the gene of calsequestrin CASQ2 in all patients by the method of analysis of restriction fragment length polymorphism was performed. The size of the left atrium, ejection fraction, the presence of chronic heart failure (CHF), the presence of dyslipidemia, the increased body mass index (BMI), myocardial hypertrophy of the left ventricle were evaluated as factors influencing the development of the tachy-brady syndrome. It was revealed that all patients in the first group had CHF (y = 4.44, p = 0.03, x = 4.88, p = 0.02), and patients with CHF FC II significantly prevailed. Dyslipidemia in patients with a combination of two types of heart rhythm disturbances is much more common (x = 6.24, p = 0.01) than in patients with only AF. The BMI was significantly different in the first and third groups (t = 2.1, CC = 55, p = 0.03). Analysis of the frequency distribution ofgenotypes of the CASQ2 gene and alleles did not reveal the presence of statistically significant differences between the groups studied. According to the research on the development of a combination of two cardiac arrhythmias of AF and SSS, such factors as CHF, BMI and the presence of dyslipidemia influence. The relationship between the development of the tachy-brady syndrome and the genetic polymorphism of the protein calsequestrin in the sample was not revealed. A population with a heterozygous type of inheritance of a protein called calsequestrin is less prone to developing a dilatation of the left atrium.

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Ferreira, Susana Lemos, João Parente Freixo, and Marta Amorim. "eP169: A case report of Ververi-Brady syndrome: Expanding the genotype and phenotype." Genetics in Medicine 24, no. 3 (March 2022): S102—S103. http://dx.doi.org/10.1016/j.gim.2022.01.205.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Föhrenbach, Melanie, Rami Abou Jamra, Arndt Borkhardt, Triantafyllia Brozou, Petra Muschke, Bernt Popp, Linda K. Rey, et al. "QRICH1 variants in Ververi‐Brady syndrome—delineation of the genotypic and phenotypic spectrum." Clinical Genetics 99, no. 1 (November 10, 2020): 199–207. http://dx.doi.org/10.1111/cge.13853.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Hasnie, Ali, Ammar Hasnie, and Ragheb Assaly. "NOT SO FAST … A CASE OF LEPTOMENINGEAL CARCINOMATOSIS MASQUERADING AS TACHY-BRADY SYNDROME." Journal of the American College of Cardiology 73, no. 9 (March 2019): 2308. http://dx.doi.org/10.1016/s0735-1097(19)32914-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Siroky, Gregory P., Alex Gold, Delphine Tang, Amit Alam, Mitchell Simon, Michael Huang, and William J. Kostis. "Left Pericardiophrenic Vein Pacing for Tachy-Brady Syndrome Due to an Obstructing Cardiac Angiosarcoma." JACC: Case Reports 2, no. 11 (September 2020): 1771–75. http://dx.doi.org/10.1016/j.jaccas.2020.07.013.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Ruciñski, P., A. Kutarski, M. Latek, B. Kamiñski, M. Szczasny, T. Widomska-Czekajska, and L. Wdowiak. "CV1 ATRIAL BASED PACING DECREASES ATRIAL FIBRILLATION RELATED HOSPITALIZATIONS AND COSTS IN BRADY-TACHY SYNDROME." Value in Health 8, no. 6 (November 2005): A2. http://dx.doi.org/10.1016/s1098-3015(10)67147-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Boriani, Giuseppe, Luigi Padeletti, Massimo Santini, Michele Gulizia, Serafino Orazi, GianLuca Botto, Alessandro Capucci, et al. "Rate control in patients with pacemaker affected by brady-tachy form of sick sinus syndrome." American Heart Journal 154, no. 1 (July 2007): 193–200. http://dx.doi.org/10.1016/j.ahj.2007.04.001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Molina-Garrido, M., C. Guillén-Ponce, and A. Carrato. "Multidimensional geriatric evaluation in elderly cancer patients and its relationship with age." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 19651. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.19651.

Повний текст джерела

Анотація:

19651 Background: Age is the major risk factor for the majority of patients with cancer. More than 50% of cancers occurs after the age of 60. Older patients are not simply old, but are geriatric patients because of interacting psychosocial and physical problems. As a consequence, the health status of old persons cannot be evaluated by merely describing the single disease or the group of age. We tested the performance of a new Comprehensive Geriatric Assessment (CGA) and its relationship with groups of age in cancer patients. Methods: Between June 2006 and December 2006, a total of 64 oncologic patients older than 75 years were approached to enrol in our study to analyze their functional, physical, mental, pharmacotherapeutic and socio-economic status and to correlate them to some groups of age: youngest-old (75 to 80 years-old), old-old (80 and 85 years-old) and oldest-old (older than 85 years). They were analysed Activities of Daily Living (ADL) measured by Barthel Scale, Instrumental Activities of Daily Living (IADL) measured by Lawton-Brody Scale, Grade of Fragility measured by Barber Scale, cognitive evaluation measured by Pfeiffer Test, and medication intake. A Chi Squared test was used for statistical analysis; p-value <0,05 was considered significative. Results: Sixty-four oncologic patients age > or = 75 years were recruited. Median age was 80.24 years (range 73.88 to 86.94). 51.6% female. Breast cancer was the most frequent diagnosis (30.2%), followed by lung cancer (19%). 29 patients (45.3%) were aged between 75 and 80 years old; 27 patients (43.5%) were between 80 and 85 years- old. There were statistic significative association between groups of age and Pfeiffer Test (p=0.037), Barber Scale (p=0.031) and medication intake (p=0.021). However, there was not a significative relationship between groups of age and Barthel Scale (p=0.052), Lawton-Brody Scale (p=0.2425), Cruz-Roja Scale (p=0,1485) or number of geriatric syndromes (p=0.129). Conclusions: This abstract reviews the findings regarding the correlation between a comprehensive geriatric assessment (CGA) and groups of age in older patients with cancer. Age per se must not be the only criterion for medical decision as it is not correlated to the health status of older cancer patients. No significant financial relationships to disclose.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Kovács, István, Sebastian Condrea, Ioana Rodean, and Daniel Cernica. "Case report. Multiple Mediastinal Arteriovenous Fistulas in a Patient with Myocardial Ischemia Symptoms and Tachy-Brady Arrhythmias." Journal Of Cardiovascular Emergencies 3, no. 1 (March 28, 2017): 44–47. http://dx.doi.org/10.1515/jce-2017-0007.

Повний текст джерела

Анотація:

AbstractArteriovenous fistulas are abnormal vascular communications between the arterial and venous system and may lead to the development of arteriovenous shunts. These malformations are extremely rare, and their diagnosis can be difficult due to the lack of symptoms or the absence of hemodynamic consequences. In many cases, arteriovenous fistulas are discovered by chance. In this brief report, we present the case of a 31-year-old male with symptoms suggestive of angina pectoris, tachycardia-bradycardia syndrome and multiple episodes of syncope. Multi-slice computed tomography revealed the presence of multiple mediastinal fistulas connecting the aorta, superior vena cava, pulmonary veins and azygos system.

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Baruch, Yoav, Shirley Horn‐Saban, Yoram Plotsky, Dani Bercovich, and Ruth Gershoni‐Baruch. "A case of Ververi‐Brady syndrome due to QRICH1 loss of function and the literature review." American Journal of Medical Genetics Part A 185, no. 6 (March 18, 2021): 1913–17. http://dx.doi.org/10.1002/ajmg.a.62184.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Azzolini, Paolo, Giuseppe Critelli, Vito De Giorgi, Giovanni B. Del Giudice, Gianfranco Ibba, Donato Melissano, Alberto Scaccia, and Andrea Puglisi. "Atrial tachyarrhythmia burden modelling by some electrophysiological parameters in pacemaker-recipient patients with Brady–Tachy syndrome." EP Europace 8, no. 7 (July 1, 2006): 474–81. http://dx.doi.org/10.1093/europace/eul065.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

DRAGO, FABRIZIO, MASSIMO STEFANO SILVETTI, GIORGIA GRUTTER, ANTONELLA DE SANTIS, MARIA GIULIA GAGLIARDI, and SALVATORE GIANNICO. "Use of DDDRP Pacing Device in Prevention and Treatment of Tachy-Brady Syndrome After Mustard Procedure." Pacing and Clinical Electrophysiology 27, no. 4 (April 2004): 530–32. http://dx.doi.org/10.1111/j.1540-8159.2004.00475.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Ariza-Solé, Albert, Carme Guerrero, Francesc Formiga, Jaime Aboal, Emad Abu-Assi, Francisco Marín, Héctor Bueno, et al. "Global Geriatric Assessment and In-Hospital Bleeding Risk in Elderly Patients with Acute Coronary Syndromes: Insights from the LONGEVO-SCA Registry." Thrombosis and Haemostasis 118, no. 03 (February 1, 2018): 581–90. http://dx.doi.org/10.1055/s-0038-1623532.

Повний текст джерела

Анотація:

Background Bleeding risk scores have shown a limited predictive ability in elderly patients with acute coronary syndromes (ACS). No study explored the role of a comprehensive geriatric assessment to predict in-hospital bleeding in this clinical setting. Methods The prospective multicentre LONGEVO-SCA registry included 532 unselected patients with non-ST segment elevation ACS (NSTEACS) aged 80 years or older. Comorbidity (Charlson index), frailty (FRAIL scale), disability (Barthel index and Lawton–Brody index), cognitive status (Pfeiffer test) and nutritional risk (mini nutritional assessment-short form test) were assessed during hospitalization. CRUSADE score was prospectively calculated for each patient. In-hospital major bleeding was defined by the CRUSADE classification. The association between geriatric syndromes and in-hospital major bleeding was assessed by logistic regression method and the area under the receiver operating characteristic curves (AUC). Results Mean age was 84.3 years (SD 4.1), 61.7% male. Most patients had increased troponin levels (84%). Mean CRUSADE bleeding score was 41 (SD 13). A total of 416 patients (78%) underwent an invasive strategy, and major bleeding was observed in 37 cases (7%). The ability of the CRUSADE score for predicting major bleeding was modest (AUC 0.64). From all aging-related variables, only comorbidity (Charlson index) was independently associated with major bleeding (per point, odds ratio: 1.23, p = 0.021). The addition of comorbidity to CRUSADE score slightly improved the ability for predicting major bleeding (AUC: 0.68). Conclusion Comorbidity was associated with major bleeding in very elderly patients with NSTEACS. The contribution of frailty, disability or nutritional risk for predicting in-hospital major bleeding was marginal.

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Sokolov, D. V., E. G. Zhelyakov, V. V. Koval'chuk, N. V. Kondratova, V. A. Snezhitskij, L. V. Kalatsei, Yu N. Belenkov, and A. V. Ardashev. "Clinical case of the cardiovascular system involvement in a patient with Charcot-Marie-Tooth disease." Kardiologiia 62, no. 5 (May 31, 2022): 67–71. http://dx.doi.org/10.18087/cardio.2022.5.n1810.

Повний текст джерела

Анотація:

Hereditary motor and sensory type 1A neuropathy (known as Charcot-Marie-Tooth disease) is a disease of peripheral nerves characterized by symptoms of progressive polyneuropathy with preferential damage of distal extremity muscles. Damage to the cardiovascular system is extremely rare and heterogenous in this pathology. This disease is not included in the list of indications for interventional antiarrhythmic aid. We could not find in available literature a clinical description of the development of sinus node dysfunction associated with this pathology. The present clinical report presents a case of detection and successful treatment of a damage to the cardiovascular system that manifested itself as sinus node dysfunction/sick sinus syndrome in the tachy-brady variant. A combination treatment approach using radiofrequency catheter ablation, implantation of a permanent pacemaker, and antiarrhythmic therapy associated with drug and non-drug treatment of motor sensory neuropathy resulted in recovery and long-term maintenance of sinus rhythm as well as in beneficial changes in the patient’s neurological status.

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Arioti, Manfredi, Giovanni Sirianni, Maria Luisa Laudisa, and Nicoletta Bianca De Cesare. "A rare but serious complication of ticagrelor therapy: a case report." European Heart Journal - Case Reports 4, no. 5 (August 20, 2020): 1–5. http://dx.doi.org/10.1093/ehjcr/ytaa156.

Повний текст джерела

Анотація:

Abstract Background Ticagrelor is a widely used P2Y12 inhibitor and represents a fundamental therapeutic agent in acute coronary syndrome treatment and selected post-percutaneous coronary intervention (PCI) cases. Dyspnoea and bradycardia are the most common side effects but the latter has been reported to be of trivial clinical significance Case summary A 51-year-old gentleman underwent PCI to left anterior descending and obtuse marginal for unstable angina receiving a loading dose of ticagrelor (180 mg). During hospital stay, whilst on telemetry monitoring, a 16 s long, symptomatic, asystolic ventricular standstill was recorded prompting ticagrelor interruption and a switch to prasugrel. Discussion Despite ventricular pauses have been reported in dedicated analyses of Phase III trials, no apparent clinical consequences were documented. However, several reports have shown that significant brady-arrhythmic events might be linked to ticagrelor administration presenting both as sino-atrial and atrio-ventricular conduction disturbances. We report a case of asystole occurring 36 h after the administration of a loading dose.

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Clement, Dominique, John Ramage, and Raj Srirajaskanthan. "Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome." Journal of Oncology 2020 (January 21, 2020): 1–11. http://dx.doi.org/10.1155/2020/8341426.

Повний текст джерела

Анотація:

Carcinoid syndrome (CS) develops in patients with hormone-producing neuroendocrine neoplasms (NENs) when hormones reach a significant level in the systemic circulation. The classical symptoms of carcinoid syndrome are flushing, diarrhoea, abdominal pain, and wheezing. Neuroendocrine neoplasms can produce multiple hormones: 5-hydroxytryptamine (serotonin) is the most well-known one, but histamine, catecholamines, and brady/tachykinins are also released. Serotonin overproduction can lead to symptoms and also stimulates fibrosis formation which can result in development of carcinoid syndrome-associated complications such as carcinoid heart disease (CaHD) and mesenteric fibrosis. Transforming growth factor beta (TGF-β) is one of the main factors in developing fibrosis, but platelet-derived growth factor (PDGF), basic fibroblast growth factor (FGF2), and connective tissue growth factor (CTGF or CCN2) are also related to fibrosis development. Treatment of CS focuses on reducing serotonin levels with somatostatin analogues (SSA’s). Telotristat ethyl and peptide receptor radionuclide therapy (PRRT) have recently become available for patients with symptoms despite being established on SSA’s. Screening for CaHD is advised, and early intervention prolongs survival. Mesenteric fibrosis is often present and associated with poorer survival, but the role for prophylactic surgery of this is unclear. Depression, anxiety, and cognitive impairment are frequently present symptoms in patients with CS but not always part of their care plan. The role of antidepressants, mainly SSRIs, is debatable, but recent retrospective studies show evidence for safe use in patients with CS. Carcinoid crisis is a life-threatening complication of CS which can appear spontaneously but mostly described during surgery, anaesthesia, chemotherapy, PRRT, and radiological procedures and may be prevented by octreotide administration.

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Novikova, T. N. "ANTIARRHYTMIC EFFICACY OF SOTALOL IN PATIENTS WITH TACHY-BRADY SYNDROME HAVING ATRIAL PACEMAKER WITH DIFFERENT ATRIAL ELECTRODE POSITION." Rational Pharmacotherapy in Cardiology 5, no. 4 (January 1, 2009): 17–20. http://dx.doi.org/10.20996/1819-6446-2009-5-4-17-20.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Archakov, E. A., R. E. Batalov, S. Yu Usenkov, M. S. Khlynin, A. V. Smorgon, S. V. Popov, and V. E. Babokin. "EFFICACY OF CATHETER ABLATION FOR PERSISTENT ATRIAL FIBRILLATION IN PATIENTS WITH DIABETES MELLITUS PRESENT WITH TACHY-BRADY SYNDROME." Complex Issues of Cardiovascular Diseases 7, no. 3 (September 21, 2018): 24–32. http://dx.doi.org/10.17802/2306-1278-2018-7-3-24-32.

Повний текст джерела

Анотація:

Aim. To estimate the efficacy of catheter ablation in patients with type 2 diabetes mellitus (T2D) present with atrial fibrillation and sick sinus syndrome (SSS) undergoing permanent pacemaker implantation.Methods. 56 patients (34 females) with persistent AF and SSS were enrolled in the study. The mean age of patients was 67.7±10.7 years. Dual chamber cardiac pacemaker with remote monitoring function were implanted in all patients. All the patients were assigned to two groups: Group 1 comprised 31 patients aged 67.3±9.6 years, and Group 2 comprised 25 patients aged 72.6±9.9 years, including 22 (39.2%) diabetic patients. 2-3 days after pacemaker implantation, group 1 patients underwent intracardiac electrophysiology study and RFA of the pulmonary vein ostia, mitral isthmus and the left atrial posterior wall. Group 2 patients received antiarrhythmic drug therapy. Results. 3 patients (9%) in Group 1 had recurrent AF within the 6-month follow-up. The efficacy of the RFA for AF was 55% (n = 17) 1 year after the indexed hospitalization. 8 patients had short paroxysmal attacks which gradually lessened and stopped after. 5 patients (21%) in Group 2 did not have any AF paroxysms within the 1-year follow-up (Х2 = 5.52, р = 0.02). All these patients received amiodarone as antiarrhythmic drug therapy, whereas the others had paroxysmal attacks. Frequent attacks in 10 patients (40%) led to a change in antiarrhythmic drug use. Hospital readmission rates for AF were 16% and 52%, respectively (Х2 = 4.15, р = 0.04). The impact of atrial and ventricular stimulation on the development of recurrent AF was statistically insignificant (atrial stimulation – X2 = 0.01, cc = 1, p = 0.90; ventricular stimulation – X2 = 0.15, cc = 1, p = 0.69). None paroxysmal attacks were recorded in 10 diabetic patients (45%) after the RFA within the 1-year follow-up.Conclusion. Catheter ablation for persistent AF and SSS treated with permanent pacemakers is highly effective and safe method. In addition, it is superior to pharmacological approach. The presence of T2D likely did not significantly affect the efficacy of RFA for persistent form of AF.

Стилі APA, Harvard, Vancouver, ISO та ін.

47

DĄBROWSKA-KUGACKA, ALICJA, EWA LEWICKA-NOWAK, PIOTR RUCIŃSKI, PAWEŁ ZAGOŻDŻON, GRZEGORZ RACZAK, and ANDRZEJ KUTARSKI. "Atrial Electromechanical Sequence and Contraction Synchrony during Single- and Multisite Atrial Pacing in Patients with Brady-Tachycardia Syndrome." Pacing and Clinical Electrophysiology 32, no. 5 (May 2009): 591–603. http://dx.doi.org/10.1111/j.1540-8159.2009.02332.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Boriani, G., M. Santini, L. Padeletti, A. Capucci, G. L. Botto, M. Gulizia, M. Biffi, R. Ricci, M. Vimercati, and A. Grammatico. "Diabetes as a comorbidity of atrial fibrillation in brady tachy syndrome: what impact on arrhythmia occurrence and outcome?" European Heart Journal 34, suppl 1 (August 2, 2013): P545. http://dx.doi.org/10.1093/eurheartj/eht307.p545.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

BORIANI, G. "P-132 Atrial tachyarrhythmia detection accuracy in ddd pacemakers implanted for brady-tachy form of sick sinus syndrome." Europace 4 (December 2003): B97—B98. http://dx.doi.org/10.1016/s1099-5129(03)91884-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Boriani, G., L. Padeletti, M. Santini, C. Martignani, C. Valzania, P. Pieragnoli, C. Ciapetti, et al. "P-132 Atrial tachyarrhythmia detection accuracy in DDD pacemakers implanted for brady-tachy form of sick sinus syndrome." EP Europace 4, Supplement_2 (December 1, 2003): B97—B98. http://dx.doi.org/10.1016/eupace/4.supplement_2.b97-c.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!